{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:35Z","timestamp":1786136015130,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacl.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:35:50Z","timestamp":1778196950000},"page":"1503-1507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison"],"prefix":"10.1016","volume":"20","author":[{"given":"Asia","family":"Sikora Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-4074","authenticated-orcid":false,"given":"Divya","family":"Pushkarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir-Masoud","family":"Pourrahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-8126","authenticated-orcid":false,"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Vera-Llonch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacl.2026.05.001_bib1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/00325481.2016.1243005","article-title":"Hypertriglyceridemia: the importance of identifying patients at risk","volume":"128","author":"Kushner","year":"2016","journal-title":"Postgrad Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.05.001_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/jgh3.12679","article-title":"Longer-term outcome of acute pancreatitis: 5\u2009years follow-up","volume":"5","author":"Patra","year":"2021","journal-title":"JGH Open"},{"issue":"19","key":"10.1016\/j.jacl.2026.05.001_bib3","first-page":"1781","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.001_bib4","first-page":"127","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.001_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jacl.2026.05.001_bib6","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","author":"Higgins","year":"2023"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2026.05.001_bib7","article-title":"ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hyper triglyceridemia","volume":"144","author":"Clifton","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.05.001_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacl.2026.05.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156521","article-title":"A Monte Carlo simulation comparing TG lowering with plozasiran versus olezarsan in patients with FCS","volume":"177","author":"Desai","year":"2026","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.jacl.2026.05.001_bib10","first-page":"382","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J\u00a0Clin\u00a0Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742600139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:03:02Z","timestamp":1786132982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742600139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S193328742600139X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}